Safety, Viremia and Immunogenicity of Sanofi Pasteur Tetravalent Dengue Vaccine in Adults Previously Exposed to Live, Attenuated Flaviviruses

被引：0
|
作者：
Qiao, M. [1 ]
Shaw, D. [1 ]
Forrat, R. [2 ]
Wartel-Tram, A. [2 ]
Lang, J. [3 ]
机构：
[1] Inst Drug Technol, CMAX, Adelaide, SA, Australia
[2] Sanofi Pasteur, Lyon, France
[3] Sanofi Pasteur, Ho Chi Minh City, Vietnam
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2008年 / 12卷
关键词：
D O I：
10.1016/j.ijid.2008.05.360
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [21] QUALITY OF THE ANTIBODY RESPONSE INDUCED BY A LIVE ATTENUATED TETRAVALENT DENGUE VACCINE IN NAIVE AND DENGUE EXPOSED INDIVIDUALS
    White, Laura
    Stoops, Mark
    Swanstrom, Jesica
    Young, Ellen
    Mukherjee, Swati
    Dean, Hansi
    Baric, Ralph
    de Silva, Aravinda
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 506 - 507
  • [22] Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City Randomized Controlled Phase 1 Trial of Safety and Immunogenicity
    Poo, Jorge
    Galan, Francisco
    Forrat, Remi
    Zambrano, Betzana
    Lang, Jean
    Dayan, Gustavo H.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : E9 - E17
  • [23] Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques
    Koraka, Penelopie
    Benton, Sabrina
    van Amerongen, Geert
    Stittelaar, Koert J.
    Osterhaus, Albert D. M. E.
    VACCINE, 2007, 25 (29) : 5409 - 5416
  • [24] Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA
    Dayan, Gustavo H.
    Thakur, Manoj
    Boaz, Mark
    Johnson, Carol
    VACCINE, 2013, 31 (44) : 5047 - 5054
  • [25] Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study
    Rupp, Richard
    Luckasen, Gary Joseph
    Kirstein, Judith Lee
    Osorio, Jorge E.
    Santangelo, Joseph D.
    Raanan, Marsha
    Smith, Mary Kathryn
    Wallace, Derek
    Gordon, Gilad S.
    Stinchcomb, Dan T.
    VACCINE, 2015, 33 (46) : 6351 - 6359
  • [26] A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults
    Gunale, Bhagwat
    Farinola, Nicholas
    Yeolekar, Leena
    Shrivastava, Shubham
    Girgis, Hanna
    Poonawalla, Cyrus S.
    Dhere, Rajeev M.
    Arankalle, Vidya
    Mishra, Akhilesh Chandra
    Mehla, Rajeev
    Kulkarni, Prasad S.
    VACCINE, 2023, 41 (38) : 5614 - 5621
  • [27] Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine
    Precioso, Alexander Roberto
    Palacios, Ricardo
    Thome, Beatriz
    Mondini, Gabriella
    Braga, Patricia
    Kalil, Jorge
    VACCINE, 2015, 33 (50) : 7121 - 7125
  • [28] Clinical development of a recombinant live attenuated tetravalent dengue vaccine
    Osorio, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 438 - 438
  • [29] Clinical development of a recombinant live attenuated tetravalent dengue vaccine
    Geeraerts, P.
    Collee, A.
    Soentjens, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 438 - 439
  • [30] Progress in live attenuated, tetravalent dengue vaccine trials in Thailand
    Bhamarapravati, N
    Sabchareon, A
    Yoksan, S
    Forrat, R
    Lang, J
    JOURNAL OF CLINICAL VIROLOGY, 2003, 28 : S25 - S25
12345